David E. Allison

Charge variants in IgG1

Leslie A. Khawli, Sirj Goswami, Ryan Hutchinson et al. · mAbs · 2010 · 417 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

Phase I Clinical Study of Pertuzumab, a Novel HER Dimerization Inhibitor, in Patients With Advanced Cancer

David B. Agus, Michael S. Gordon, Charles Taylor et al. · Journal of Clinical Oncology · 2005 · 388 citations · Full text

Medicine, Oncology, Pharmacology +7

Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab

Camellia Adams, David E. Allison, Kelly M. Flagella et al. · Cancer Immunology Immunotherapy · 2005 · 315 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +14

Clinical Activity of Pertuzumab (rhuMAb 2C4), a HER Dimerization Inhibitor, in Advanced Ovarian Cancer: Potential Predictive Relationship With Tumor HER2 Activation Status

Michael S. Gordon, Daniela Matei, Carol Aghajanian et al. · Journal of Clinical Oncology · 2006 · 249 citations

Medicine, Oncology, Pharmacology +15

A Guide to Rational Dosing of Monoclonal Antibodies

Shuang Bai, Karin Jorga, Denise Jin et al. · Clinical Pharmacokinetics · 2012 · 163 citations

Pharmacy, Pharmacokinetics, Pharmacology +14